Pearl Steinzor

With potential lung cancer nodules sometimes slipping through the cracks, educating stakeholders about artificial intelligence (AI) that can catch nodules early could be helpful in cancer treatment.

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, shares how one mobile health care initiative is addressing critical barriers to medical access for underserved populations.

A groundbreaking trial shows tumor-treating fields enhance survival and quality of life for patients with locally advanced pancreatic cancer.

US claims data show patients with generalized pustular psoriasis (GPP) face up to a 4-fold higher mortality risk compared with the general population.

Ponatinib shows promising results in achieving MRD negativity and improved event-free survival in Ph+ ALL patients compared to imatinib, according to ASCO findings.

A circulating tumor DNA (ctDNA) blood test demonstrated high sensitivity and specificity for colorectal cancer (CRC) detection in a large average-risk population, study finds.

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide.

Developments in artificial intelligence (AI) can help clinicians to diagnose thoracic conditions that may be miss on first glance.

Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre, discusses a phase 3 clinical trial investigating amivantamab in metastatic colorectal cancer.

Jill Feldman, cofounder and president, EGFR Resisters, shares the importance of being proactive in managing dermatologic toxicities in epidermal growth factor receptor (EGFR)–positive lung cancer.

The value of the combination of albuterol/budesonide is high due to its alleviating of corticosteroid burden, according to Reynold Panettieri Jr, MD.

Danny Rischin, MD, medical oncologist, clinician researcher, Peter McCallum Cancer Centre, discusses a novel adjuvant treatment approach for patients with locally advanced cutaneous squamous cell carcinoma (CSCC).

The landscape of treatment for bronchiectasis could change significantly with the approval of brensocatib, offering a more direct method of stemming the adverse events related to the condition, explains James Chalmers, MD, University of Dundee.

Ibrahim Aldoss, MD, associate professor, City of Hope, explores recent findings on ponatinib as a first-line treatment for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

Cemiplimab significantly enhances disease-free survival in high-risk cSCC patients, reducing recurrence and metastasis risks, according to findings presented at ASCO.

Different dosages of brensocatib proved effective in treating people living with bronchiectasis when studied in the ASPEN trial.

Vincent Picozzi, MD, medical oncologist and director of the Pancreaticobiliary Program at Virginia Mason, discusses findings from the PANOVA-3 trial, which represents a significant breakthrough in locally advanced pancreatic cancer (LA-PAC) treatment.

Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami Cancer Institute of Baptist Health South Florida, discusses a groundbreaking clinical trial for non-small cell lung cancer (NSCLC) brain metastases.

Sanjay Goel, MD, MS, professor of medicine at Robert Wood Johnson Medical School and medical oncologist at Rutgers Cancer Institute, anticipates groundbreaking data at the American Society of Clinical Oncology (ASCO) 2025 meeting, with plenary sessions spotlighting research that could immediately impact cancer care.

The approval of brensocatib for use in patients with bronchiectasis could offer the first treatment directly addressing the roots of the condition.

Patients with chronic conditions are less likely to be diagnosed via screening and face higher mortality when cancer is detected in emergency settings, according to one study.

Attendees at the American Thoracic Society (ATS) 2025 International Conference highlight global networking, scientific advancements, and professional development at this year's meeting.

Once-daily roflumilast provides skin clearance and rapid itch relief with no limitation on duration of use.

Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC, shares trial findings from the FIBRONEER-IPF (NCT05321069) and FIBRONEER-ILD (NCT05321082) studies on nerandomilast.

Matthew Viggiano, MD, internal medicine resident, Temple University Hospital, shares findings on a study in which female patients with interstitial lung disease (ILD) admitted to the intensive care unit (ICU) experienced significantly lower mortality rates and shorter hospital stays than male patients with ILD.

Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital, discusses how early intervention within 12 hours improved hemodynamic measurements and clinical outcomes in patients with pulmonary embolism.

M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill, shares promising results of ensifentrine in helping patients with insufficient chronic obstructive pulmonary disease (COPD) control.

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, discusses the value of the win ratio approach in evaluating treatment effects in chronic obstructive pulmonary disease (COPD).

Michael Goulet, DO, pulmonary and critical care fellow, Temple University Hospital, shares findings on the impact of wildfire smoke on hospital admissions and health care utilization in the Northeast.

Despite advances in diabetes care, new research reveals persistent economic disadvantages for middle-aged adults living with the condition.